Compare Gilead Sciences, Inc. (GILD) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs United Microelectronics Corp — how do they compare? Gilead Sciences, Inc. trades at $133.44 (market cap $163.51B), while United Microelectronics Corp trades at $22.28 (market cap $65.12B). The key difference: Gilead Sciences, Inc. is far larger — about 2.5× United Microelectronics Corp's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | UMC | |
|---|---|---|
Market Cap | $163.51B | $65.12B |
Sector | Health | Technology |
52-Week High | $155.80 | $28.02 |
52-Week Low | $108.22 | $6.58 |
Enterprise Value | $178.05B | $62.70B |
Dividend Yield | 2.49% | 1.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
UMC trades at $22.26, down 6.63% over the past day, with a bullish technical signal driven by moving averages and positive momentum indicators. The company reported Q1 2026 EPS of $0.20, beating expectations, and maintains strong profitability with a 20.25% net income margin. Recent news highlights mass production milestones in silicon photonics and 14nm eHV FinFET platform advancements, supporting growth in AI and automotive demand.
Outlook remains positive with solid revenue growth and margin stability, though valuation ratios like P/E of 40.46 suggest premium pricing. Risks include competitive pressures and cyclical semiconductor demand. Analyst consensus is mixed with 26.7% buy ratings, indicating cautious optimism amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
